{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:21:10Z","timestamp":1783948870130,"version":"3.55.0"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2015,6,9]],"date-time":"2015-06-09T00:00:00Z","timestamp":1433808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0128673","type":"journal-article","created":{"date-parts":[[2015,6,9]],"date-time":"2015-06-09T17:59:34Z","timestamp":1433872774000},"page":"e0128673","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prophylactic Effect of Lamivudine for Chemotherapy-Induced Hepatitis B Reactivation in Breast Cancer: A Meta-Analysis"],"prefix":"10.1371","volume":"10","author":[{"given":"Wei","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruohui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxiao","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xigang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,6,9]]},"reference":[{"key":"ref1","first-page":"911","article-title":"Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients","volume":"73","author":"JY Lau","year":"1989","journal-title":"Q J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.1999.17.1.394","article-title":"Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem","volume":"17","author":"R Liang","year":"1999","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/jmv.2060","article-title":"Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis","volume":"65","author":"W Yeo","year":"2001","journal-title":"J Med Virol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1023\/A:1008206519571","article-title":"Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin&apos;s lymphoma","volume":"9","author":"FL Clark","year":"1998","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/(SICI)1096-9071(199911)59:3<263::AID-JMV1>3.0.CO;2-X","article-title":"Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy","volume":"59","author":"W Yeo","year":"1999","journal-title":"J Med Virol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1572-0241.1999.00808.x","article-title":"Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection","volume":"94","author":"A Ahmed","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/hep.22106","article-title":"A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin&apos;s lymphoma: a randomized trial","volume":"47","author":"C Hsu","year":"2008","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","article-title":"Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors","volume":"62","author":"W Yeo","year":"2000","journal-title":"J Med Virol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1743-422X-11-59","article-title":"Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis","volume":"11","author":"F Liu","year":"2014","journal-title":"Virol J"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10549-011-1455-9","article-title":"A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?","volume":"127","author":"M Long","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/bjc.2011.4","article-title":"Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy","volume":"104","author":"J Yun","year":"2011","journal-title":"Br J Cancer"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s12282-012-0417-3","article-title":"Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy","volume":"21","author":"HJ Lee","year":"2014","journal-title":"Breast Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10549-004-0725-1","article-title":"Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients","volume":"88","author":"W Yeo","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s00520-010-1019-2","article-title":"Preventing chemotherapy-induced hepatitis B reactivation in breast cancer patients: a prospective comparison of prophylactic versus deferred preemptive lamivudine","volume":"19","author":"SH Tsai","year":"2011","journal-title":"Support Care Cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1478-3231.2004.0964.x","article-title":"Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration","volume":"24","author":"MS Dai","year":"2004","journal-title":"Liver Int"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/1756283X12450245","article-title":"Management of hepatitis B reactivation in patients receiving cancer chemotherapy","volume":"5","author":"YW Huang","year":"2012","journal-title":"Therap Adv Gastroenterol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1365-2036.2006.03081.x","article-title":"Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection","volume":"24","author":"HE Kohrt","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1352-0504.2003.00467.x","article-title":"High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy","volume":"11","author":"S Zhong","year":"2004","journal-title":"J Viral Hepat"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1002\/1097-0142(20011201)92:11<2927::AID-CNCR10109>3.0.CO;2-W","article-title":"Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients","volume":"92","author":"MS Dai","year":"2001","journal-title":"Cancer"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1053\/j.gastro.2008.02.075","article-title":"Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT","volume":"134","author":"M Kumar","year":"2008","journal-title":"Gastroenterology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1046\/j.1365-2141.2001.03099.x","article-title":"Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy","volume":"115","author":"G Rossi","year":"2001","journal-title":"Br J Haematol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/jjco\/hyr106","article-title":"Updated longitudinal data on acute exacerbation of chronic hepatitis B in patients with breast cancer receiving anthracycline-based adjuvant chemotherapy: therapeutic vs. pre-emptive use of lamivudine","volume":"41","author":"BS Sohn","year":"2000","journal-title":"Jpn J Clin Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1053\/jhep.2000.17912","article-title":"Long-term therapy of chronic hepatitis B with lamivudine","volume":"32","author":"DT Lau","year":"2000","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1053\/j.gastro.2003.09.026","article-title":"Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy","volume":"125","author":"GK Lau","year":"2003","journal-title":"Gastroenterology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/hep.510270628","article-title":"Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group","volume":"27","author":"MI Allen","year":"1998","journal-title":"Hepatology"},{"key":"ref26","first-page":"714","article-title":"Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo","volume":"24","author":"GA Tipples","year":"1996","journal-title":"Hepatology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0168-8278(00)80076-8","article-title":"Long-term follow-up of patients with anti-HBe\/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine","volume":"32","author":"T Santantonio","year":"2000","journal-title":"J Hepatol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"AS Lok","year":"2007","journal-title":"Hepatology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0128673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T11:25:27Z","timestamp":1540293927000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0128673"}},"subtitle":[],"editor":[{"given":"Yury E","family":"Khudyakov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,6,9]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,6,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0128673","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,9]]}}}